Pre-RT Pulmonary Function Tests (PFTs) are Better Indicators of Severe Pulmonary Fibrosis than Dosimetric Parameters in Patients with Lung Cancer

2008 ◽  
Vol 72 (1) ◽  
pp. S435-S436
Author(s):  
X.L. Xu ◽  
L. Xie ◽  
M. Fan ◽  
G. Jiang
Keyword(s):  
Lung Cancer ◽  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Pulmonary Function Tests ◽  
Function Tests

Pulmonary Function Tests and Idiopathic Pulmonary Fibrosis

CHEST Journal ◽  
1997 ◽  
Vol 111 (1) ◽  
pp. 7-8 ◽  
Author(s):  
Steven H. Kirtland ◽  
Richard H. Winterbauer
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Pulmonary Function Tests ◽  
Function Tests

Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer

CHEST Journal ◽  
2009 ◽  
Vol 135 (6) ◽  
pp. 1588-1595 ◽  
Author(s):  
M. Patricia Rivera ◽  
Frank C. Detterbeck ◽  
Mark A. Socinski ◽  
Dominic T. Moore ◽  
Martin J. Edelman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Function ◽  
Small Cell Lung Cancer ◽  
Preoperative Chemotherapy ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Pulmonary Function Tests ◽  
Small Cell ◽  
Small Cell Lung ◽  
Function Tests

Quantitative CT analysis of honeycombing area in idiopathic pulmonary fibrosis: Correlations with pulmonary function tests

2016 ◽  
Vol 85 (1) ◽  
pp. 125-130 ◽  
Author(s):  
Hiroaki Nakagawa ◽  
Yukihiro Nagatani ◽  
Masashi Takahashi ◽  
Emiko Ogawa ◽  
Nguyen Van Tho ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Pulmonary Function Tests ◽  
Quantitative Ct ◽  
Function Tests ◽  
Ct Analysis ◽  
Quantitative Ct Analysis

scholarly journals Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder

2019 ◽  
Vol 5 (4) ◽  
pp. 00209-2019 ◽  
Author(s):  
Neelam Giri ◽  
Sandhiya Ravichandran ◽  
Youjin Wang ◽  
Shahinaz M. Gadalla ◽  
Blanche P. Alter ◽  
...  
Keyword(s):  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Pulmonary Disease ◽  
Cumulative Incidence ◽  
Pulmonary Function Tests ◽  
Dyskeratosis Congenita ◽  
Telomere Maintenance ◽  
Genetic Characteristics ◽  
Function Tests ◽  
Telomere Biology

Pulmonary fibrosis and pulmonary arteriovenous malformations are known manifestations of dyskeratosis congenita (DC), a telomere biology disorder (TBD) and inherited bone marrow failure syndrome caused by germline mutations in telomere maintenance genes resulting in very short telomeres. Baseline pulmonary function tests (PFTs) and long-term clinical outcomes have not been thoroughly studied in DC/TBDs.In this retrospective study, 43 patients with DC and 67 unaffected relatives underwent baseline PFTs and were followed for a median of 8 years (range 1–14). Logistic regression and competing risk models were used to compare PFT results in relation to clinical and genetic characteristics, and patient outcomes.Restrictive abnormalities on spirometry and moderate-to-severe reduction in diffusing capacity of the lung for carbon monoxide were significantly more frequent in patients with DC than relatives (42% versus 12%; p=0.008). The cumulative incidence of pulmonary disease by age 20 years was 55% in patients with DC with baseline PFT abnormalities compared with 17% in those with normal PFTs (p=0.02). None of the relatives developed pulmonary disease. X-linked recessive, autosomal recessive inheritance or heterozygous TINF2 variants were associated with early-onset pulmonary disease that mainly developed after haematopoietic cell transplantation (HCT). Overall, seven of 14 patients developed pulmonary disease post-HCT at a median of 4.7 years (range 0.7–12). The cumulative incidence of pulmonary fibrosis in patients with heterozygous non-TINF2 pathogenic variants was 70% by age 60 years.Baseline PFT abnormalities are common in patients with DC and associated with progression to significant pulmonary disease. Prospective studies are warranted to facilitate clinical trial development for patients with DC and related TBDs.

IMPACT OF PRE-OPERATIVE CHEMOTHERAPY ON PULMONARY FUNCTION TESTS IN RESECTABLE EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)

CHEST Journal ◽  
2008 ◽  
Vol 134 (4) ◽  
pp. 74P
Author(s):  
M.P. Rivera ◽  
Frank C. Detterbeck ◽  
Mark A. Socinski ◽  
Dominic T. Moore ◽  
Martin J. Edelman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Function ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Pulmonary Function Tests ◽  
Small Cell ◽  
Small Cell Lung ◽  
Function Tests

scholarly journals Frequency of restrictive pulmonary function tests in patients with chronic Hepatitis C

2021 ◽  
Vol 1 (4) ◽  
pp. e223
Author(s):  
Shahid Hamid ◽  
Khalid Mehmood Khan ◽  
Fawad Ahmed ◽  
Asia Firdous
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Chronic Hepatitis C ◽  
Lung Fibrosis ◽  
Pulmonary Function Tests ◽  
Hepatitis C Infection ◽  
Function Tests ◽  
Restrictive Pattern

Hepatis C infection is a common health problem world wide and is the major cause of chronic liver disease in Pakistan. Common complications of chronic hepatitis c infection are cirrhosis, ascities and hepatocellular carcinoma. Also HCV infection is associated with several extra hepatic manifestations including interstitial lung fibrosis. It has been found that frequency of pulmonary fibrosis is increased in patients with cirrhosis of liver as the stage of cirrhosis advances.This lung fibrosis can cause restrictive pattern of pulmonary function tests. This study was conducted to determine frequency of restrictive pulmonary function in patients with different stages of chronic hepatitis C  infection, based on child pough classification. Study design This is descriptive case study Method 99 patients of age range 20 to 80 year, both males and females having chronic hepatitis C infection and interferon based treatment naïve patients were included from outpatient and inpatient department were selected. Patients were divided into three groups according to child’s criteria i.e. group A, group B, and group C. Pulmonary function tests were performed on patients in all three groups to look for  FEV1/FVC ratio in all patients. FEV1/FVC ratio  more than 80 was considered as restrictive pulmonary function. Results Out of 99 patients 32(35%) were found to have restrictive pattern of pulmonary functions Conclusion Chronic hepatitis C infection is associated with restrictive pattern of pulmonary function, suggestive of pulmonary fibrosis.

Pulmonary toxicity in patients receiving docetaxel chemotherapy

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e13532-e13532
Author(s):  
U. Kefeli ◽  
P. F. Yumuk ◽  
B. Ceyhan ◽  
F. Dane ◽  
B. Eroglu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pulmonary Function ◽  
Cumulative Dose ◽  
Pulmonary Toxicity ◽  
Pulmonary Function Tests ◽  
Post Treatment ◽  
Function Tests ◽  
Significant Difference ◽  
Docetaxel Treatment ◽  
Docetaxel Chemotherapy

e13532 Background: Docetaxel is used widely as monotherapy or in combination for the treatment of various types of cancers. Although rarely observed, pulmonary toxicity can be seen with docetaxel. This side effect had been reported mostly in non-small cell lung cancer patients receiving docetaxel. We aimed to investigate the pulmonary toxicity in patients receiving docetaxel chemotherapy other than lung cancer. Methods: 34 patients were investigated prospectively to demonstrate the pulmonary toxicity of docetaxel. Pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) scans were applied to all patients before chemotherapy and 14 - 21 days after completion of treatment. We used a HRCT scoring system that was based on the previous studies. All HRCT images were reviewed by two different observers. Results: We have seen no pulmonary symptoms that may reflect pulmonary toxicity in 34 patients. There were statistically significant differences between pre- and post-treatment values of FEV1 (L/sec) (p<0.05), FEV1/FVC (%) (p<0.05), FEF25–75 (L/sec) (p<0.01), FEF25–75 (%) (p<0,01), DLCO (mL/mmHg/min) (p<0.001), DLCO (%) (p<0.001), DLCO/VA (DLCO/L) (p<0.05), and DLCO/VA (%) (p<0.05). Also, there was a statistically significant difference between the pre- and post-treatment HRCT scores. The differences between pre- and post- treatment values of pulmonary function tests were not correlated with the number of docetaxel cycles and cumulative dose. There was a statistical relationship between number of docetaxel cycles (r =0.468, p<0.0001), docetaxel cumulative dose (r=0,596, p<0.0001) and HRCT scores after completion of docetaxel treatment. Conclusions: Although we have shown that docetaxel treatment causes a decline in PFTs and worsens HRCT scores, the symptoms of patients were not consistent with these differences. Therefore, it should be noted that the negative effects of docetaxel on PFTs and HRCT scores should be investigated by increasing the number of patients. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document